19.11.2015
- A further regulatory milestone has been achieved by Merck KGaA and Pfizer after the US Food and Drug Administration (FDA) designated their potential skin cancer treatment avelumab...
06.02.2015
- US regulators intend to rescind the "breakthrough therapy" designation for Merck & Co's hepatitis C combination treatment, a decision that could delay approval of the product by...
